Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the duodenum.
Biomarker and diagnostic research for duodenal neuroendocrine tumor, well differentiated, low or intermediate grade has been reported in the published literature.
No clinical trials have been registered for duodenal neuroendocrine tumor, well differentiated, low or intermediate grade.
259 publications have been identified in PubMed for duodenal neuroendocrine tumor, well differentiated, low or intermediate grade. Research spans Clinical Trial Publication (26%), Review / Meta-Analysis (19%), and Diagnostic / Biomarker (18%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 67 | 26% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:39 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
48 |
19% |
Testing and diagnosis research | 46 | 18% |
Laboratory research | 38 | 15% |
Disease patterns and progression | 37 | 14% |
Patient case studies | 22 | 8% |
New treatment approaches | 1 | 0% |
Mukherjee S (2026). [PMID: 41450867](https://pubmed.ncbi.nlm.nih.gov/41450867/). *Ophthalmol Sci*. [Basic Science / Preclinical]
Amin A (2026). [PMID: 41536013](https://pubmed.ncbi.nlm.nih.gov/41536013/). *Current opinion in urology*. [Review / Meta-Analysis]
Adhami M (2026). [PMID: 41684641](https://pubmed.ncbi.nlm.nih.gov/41684641/). *BJUI compass*. [Clinical Trial Publication]
Heckmann N (2026). [PMID: 41188544](https://pubmed.ncbi.nlm.nih.gov/41188544/). *Prostate cancer and prostatic diseases*. [Clinical Trial Publication]
Sheng YH (2026). [PMID: 41693974](https://pubmed.ncbi.nlm.nih.gov/41693974/). *World journal of gastroenterology*. [Clinical Trial Publication]
Hou G (2026). [PMID: 41134321](https://pubmed.ncbi.nlm.nih.gov/41134321/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]
Nilsson P (2026). [PMID: 41655576](https://pubmed.ncbi.nlm.nih.gov/41655576/). *The Lancet. Oncology*. [Epidemiology / Natural History]
Tanguy R (2026). [PMID: 42115465](https://pubmed.ncbi.nlm.nih.gov/42115465/). *Adv Tech Stand Neurosurg*. [Review / Meta-Analysis]
Scuderi S (2026). [PMID: 41002165](https://pubmed.ncbi.nlm.nih.gov/41002165/). *Journal of the National Cancer Institute*. [Diagnostic / Biomarker]
Sountoulidis A (2026). [PMID: 41851103](https://pubmed.ncbi.nlm.nih.gov/41851103/). *Nat Commun*. [Basic Science / Preclinical]